Patent intelligence · US
US 10934337
Anti-BCMA chimeric antigen receptors
Anti-BCMA chimeric antigen receptors
Patent details — US 10934337
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 2, 2021
- Expiration
- Feb 25, 2041
- Applicant
- Cartesian Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00
Quick answer
US 10934337 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Mar 2, 2021. Expires Feb 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cartesian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955, A61K39/39558
More from Cartesian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10934337?
US 10934337 (Anti-BCMA chimeric antigen receptors) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Mar 2, 2021. Expires Feb 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10934337?
Cartesian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 10934337 expire?
Our index shows an expiration date of Feb 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.